On June 28, Weiyuan and Bojian announced that the humanized anti-soluble amyloid-β (Aβ) monoclonal antibody Lennyibao (Lunkanai monoclonal antibody) was launched in China. The drug was approved by the China National Medical Products Administration in January 2024 for the treatment of mild cognitive impairment and mild dementia caused by Alzheimer's disease. In China, Lunkanai monoclonal antibody will be first sold in the self-pay market. Weiyuan will cooperate with a large medical insurance company to develop and launch a medical insurance plan specifically for Alzheimer's disease, covering some medical expenses.
卫材中国：将就阿尔茨海默病新药仑卡奈单抗推出一款医疗保险计划
Weiyuan China: Will launch a medical insurance plan for a new pharmaceutical Lunakane monoclonal antibody for Alzheimer's disease.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.